Literature DB >> 19427997

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.

Juan F M Leal1, Verónica García-Hernández, Victoria Moneo, Alberto Domingo, Juan Antonio Bueren-Calabuig, Ana Negri, Federico Gago, María José Guillén-Navarro, Pablo Avilés, Carmen Cuevas, Luis Francisco García-Fernández, Carlos María Galmarini.   

Abstract

Zalypsis is a new synthetic alkaloid tetrahydroisoquinoline antibiotic that has a reactive carbinolamine group. This functionality can lead to the formation of a covalent bond with the amino group of selected guanines in the DNA double helix, both in the absence and in the presence of methylated cytosines. The resulting complex is additionally stabilized by the establishment of one or more hydrogen bonds with adjacent nucleotides in the opposite strand as well as by van der Waals interactions within the minor groove. Fluorescence-based thermal denaturation experiments demonstrated that the most favorable DNA triplets for covalent adduct formation are AGG, GGC, AGC, CGG and TGG, and these preferences could be rationalized on the basis of molecular modeling results. Zalypsis-DNA adducts eventually give rise to double-strand breaks, triggering S-phase accumulation and apoptotic cell death. The potent cytotoxic activity of Zalypsis was ascertained in a 24 cell line panel. The mean IC(50) value was 7nM and leukemia and stomach tumor cell lines were amongst the most sensitive. Zalypsis administration in four murine xenograft models of human cancer demonstrates significant tumor growth inhibition that is highest in the Hs746t gastric cancer cell line with no weight loss of treated animals. Taken together, these results indicate that the potent antitumor activity of Zalypsis supports its current development in the clinic as an anticancer agent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427997     DOI: 10.1016/j.bcp.2009.04.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.

Authors:  J F M Leal; M Martínez-Díez; V García-Hernández; V Moneo; A Domingo; J A Bueren-Calabuig; A Negri; F Gago; M J Guillén-Navarro; P Avilés; C Cuevas; L F García-Fernández; C M Galmarini
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.

Authors:  Robin L Jones; Stefano Ferrari; Jean Yves Blay; Fariba Navid; Pilar Lardelli; Vicente Alfaro; Mariano Siguero; Neelesh Soman; Sant P Chawla
Journal:  Invest New Drugs       Date:  2013-11-01       Impact factor: 3.850

4.  Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

Authors:  Enrique Colado; Teresa Paíno; Patricia Maiso; Enrique M Ocio; Xi Chen; Stela Alvarez-Fernández; Norma C Gutiérrez; Jesús Martín-Sánchez; Juan Flores-Montero; Laura San Segundo; Mercedes Garayoa; Diego Fernández-Lázaro; Maria-Belen Vidriales; Carlos M Galmarini; Pablo Avilés; Carmen Cuevas; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

5.  Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).

Authors:  Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

6.  Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Authors:  Christophe Massard; Jane Margetts; Nadia Amellal; Yvette Drew; Ratislav Bahleda; Peter Stephens; Peter Stevens; Jean Pierre Armand; Hilary Calvert; Jean Charles Soria; Cinthya Coronado; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Carlos Fernández-Teruel; Ruth Plummer
Journal:  Invest New Drugs       Date:  2012-06-12       Impact factor: 3.850

7.  Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Authors:  Sandra Martínez; Laura Pérez; Carlos M Galmarini; Miguel Aracil; Juan C Tercero; Federico Gago; Beatriz Albella; Juan A Bueren
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

8.  Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.

Authors:  Ramón Salazar; Antonio Calles; Marta Gil; Ignacio Durán; Margarita García; Manuel Hidalgo; Cinthya Coronado; Vicente Alfaro; Mariano Siguero; Carlos Fernández-Teruel; Raquel Prados; Emiliano Calvo
Journal:  Invest New Drugs       Date:  2014-02-19       Impact factor: 3.850

9.  First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Authors:  T A Yap; H Cortes-Funes; H Shaw; R Rodriguez; D Olmos; R Lal; P C Fong; D S Tan; D Harris; J Capdevila; C Coronado; V Alfaro; A Soto-Matos; C Fernández-Teruel; M Siguero; J M Tabernero; L Paz-Ares; J S de Bono; J A López-Martin
Journal:  Br J Cancer       Date:  2012-04-10       Impact factor: 7.640

10.  Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations.

Authors:  Juan A Bueren-Calabuig; Christophe Giraudon; Carlos M Galmarini; Jean Marc Egly; Federico Gago
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.